Free Trial
→ The Man I Turn to In Times Like This (From Stansberry Research) (Ad)

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Written by MarketBeat Staff
May 18, 2023

Key Points

  • Biotech stocks have a reputation for being high risk, high reward.
  • Many of the stocks Wall Street thinks can double (or better) over the next 12 months are biotechs.
  • Although Denali has yet to commercialize a product, analysts are encouraged by its progress and collaborations with major biopharmaceutical players.
  • Since its May 4th report, seven analysts have reiterated buy ratings on Ultragenyx compared to one hold.
  • Five stocks we like better than Denali Therapeutics.

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Upgrade Now See Benefits

Already have an account? Log in here.

Should You Invest $1,000 in Denali Therapeutics Right Now?

Before you consider Denali Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.

While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Denali Therapeutics (DNLI)
3.8344 of 5 stars		$14.62+1.3%N/A-5.30Buy$33.79
Ultragenyx Pharmaceutical (RARE)
4.2417 of 5 stars		$36.28+0.8%N/A-5.72Moderate Buy$92.79
Sarepta Therapeutics (SRPT)
4.7213 of 5 stars		$38.10+4.3%N/A30.48Moderate Buy$131.22
Pfizer (PFE)
4.9992 of 5 stars		$22.47-0.3%7.65%15.94Moderate Buy$29.17
Exelixis (EXEL)
4.1599 of 5 stars		$36.78+0.8%N/A20.78Hold$37.59
Moderna (MRNA)
4.4763 of 5 stars		$24.97+2.4%N/A-2.69Hold$53.95
United Therapeutics (UTHR)
4.9842 of 5 stars		$307.60-0.1%N/A13.51Moderate Buy$392.00
Biogen (BIIB)
4.7197 of 5 stars		$118.95+0.5%N/A10.63Hold$191.30
Sanofi (SNY)
4.3239 of 5 stars		$50.32-0.4%3.18%20.21Buy$63.33
Eli Lilly and Company (LLY)
4.991 of 5 stars		$756.13+0.6%0.79%64.57Moderate Buy$1,002.80
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

5 Stocks You’ve Never Heard Of That I’m Buying Nonstop in 2025
3 Sectors With Massive Momentum You Can’t Afford to Miss
Palantir’s Big Moves: Profit-Taking, Price Targets & AI Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines